AI assistant
IONIS PHARMACEUTICALS INC — Director's Dealing 2015
Jan 20, 2015
30591_dirs_2015-01-20_99618f8f-7307-4d7c-85ea-97aae4ae5f86.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ISIS PHARMACEUTICALS INC (ISIS)
CIK: 0000874015
Period of Report: 2015-01-15
Reporting Person: Boyce Sarah (Chief Business Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-01-15 | Restricted Stock Units | $ | A | 8750 | Acquired | Common Stock (8750) | Direct |
Footnotes
F1: Each Restricted Stock Unit represents a contingent right to receive one share of Isis common stock, or its equivalent cash value.
F2: Grant 1/15/2015 to reporting person of Restricted Stock Units under the Isis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2016. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2019. The RSU is vested as to 0 shares on January 15, 2015.